In a Prospective, Multicenter Study, the 31-GEP Identified Patients at Increased Risk of Tumor Recurrence and Added Significant Prognostic Value to AJCC Staging. J of Skin 2024, 8 (6), s504. https://doi.org/10.25251/skin.8.supp.504.